Atossa Therapeutics, Inc.
ATOS
$5.16
-$0.34-6.18%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -10.94M | -8.69M | -8.42M | -6.72M | -6.35M |
| Total Depreciation and Amortization | 4.00K | 4.00K | 4.00K | 4.00K | 4.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 503.00K | 784.00K | 796.00K | 563.00K | 778.00K |
| Change in Net Operating Assets | -109.00K | 1.90M | 364.00K | 192.00K | -1.49M |
| Cash from Operations | -10.54M | -6.01M | -7.26M | -5.96M | -7.05M |
| Capital Expenditure | -7.00K | -7.00K | 0.00 | -9.00K | 0.00 |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -7.00K | -7.00K | 0.00 | -9.00K | 0.00 |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | 3.37M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | 3.37M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -10.55M | -6.01M | -7.26M | -5.97M | -3.68M |